Bionaturis (BNT-MAB), an international reference company developing biological drugs, has released the 2013 Annual Report.

Victor Infante, Bionaturis’ CEO, has commented about the results: “The important point here is that our performance supports our strategy. Now the focus is on the internationalization process and to achieve the milestones needed to move forward our BNT programs to the market. We are on the right track. We keep estimations to increase our revenues around 400% this year”.

The 2013 annual report goes over the main milestones achieved during 2013 and the outlook for 2014 and beyond.

Key figures

Revenue for 2013 was €1.75 million as compared to €1.4 million for 2012, an increase of €0.35 million, or 25%. Net sales for 2013 was €0.89 million as compared to €0.44 million for 2012, an increase of 96%.

In 2013 EBITDA was €721 thousand as compared to €-246 thousand for 2012, an increase of €+ 967 thousand. In 2013 Net Result was €473 thousand as compared to €-342 thousand for 2012, an increase of €815 thousand.

Click here to get the full report